Trial · NCT07891559
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment | Recruitment period (November 2025 to July 2026) | Number of eligible veterans enrolled (consented) during the recruitment period, against the target of 20 completers. |
| Primary | Retention | From consent through Training Day 3 (about 5 days) | Percentage of consented participants who complete all study sessions. |
| Primary | Protocol adherence | Training Days 1 to 3 | Percentage of participants who begin training and complete all three training days. |
| Primary | Number of participants rating the suppression strategy as useful outside the laboratory | End of Training Day 3 | Single post-training yes/no item: "Do you think that the suppression strategy you learned through the course of this training is useful or helpful to use outside the lab in your own life?" Reported as the number and percentage of participants answering Yes; a higher percentage indicates greater acceptability. |
| Primary | Number of completers whose training was delivered on the protocol-specified schedule | From stimulus preparation through Training Day 3 (about 5 days) | Delivery was recorded as per protocol when stimulus preparation was followed by three training days on consecutive days, as specified in the protocol. Reported as the number and percentage of completers; a higher percentage indicates greater fidelity of delivery. |
| Primary | Adverse events | From consent through Training Day 3 | Number of participants with serious adverse events. |
| Primary | Number of participants likely to re-use the suppression strategy, assessed by a 5-point rating item | End of Training Day 3 | Single post-training item: "How likely are you to re-use the suppression strategy you learned to decrease your anxiety or thoughts about the negative events in your life?" Rated from 1 (Very unlikely) to 5 (Very likely); minimum 1, maximum 5; higher scores indicate greater likelihood of re-use (a better outcome). Reported as the number and percentage of participants rating Likely (4) or Very likely (5). |
| Primary | Self-rated effectiveness at stopping thoughts about upsetting events, assessed by a 5-point rating item | End of Training Day 3 | Participants rated how effectively they could stop thoughts about their upsetting events at the beginning of training (Training Day 1, rated retrospectively) and at the end of training (Training Day 3). Each rating ranges from 1 (Not at all effective) to 5 (Extremely effective); higher scores indicate better self-rated effectiveness (a better outcome). |
| Primary | Number of completers confirming the suppression-strategy instruction they were assigned, assessed by a post-training yes/no item | Training Day 3 | After training, participants were shown the strategy instruction for their assigned condition and asked to confirm (Yes/No) that it was the strategy they had practiced. Reported as the number and percentage answering Yes; a higher percentage indicates more accurate delivery of the assigned instruction. |
| Secondary | Warwick-Edinburgh Mental Well-being Scale (WEMWBS) | Baseline (introductory session) and end of Training Day 3 (about 5 days) | Change in total score (range 14 to 70; higher scores indicate better well-being). |
| Secondary | Positive and Negative Affect Schedule (PANAS) | Baseline (introductory session) and end of Training Day 3 (about 5 days) | Change in positive affect and negative affect subscale scores (10 items each, rated 1 to 5; each subscale range 10 to 50). Higher positive-affect scores indicate a better outcome; higher negative-affect scores indicate a worse outcome. |
| Secondary | State-Trait Anxiety Inventory, state form (STAI-S) | Baseline (introductory session) and end of Training Day 3 (about 5 days) | Change in total score (range 20 to 80; higher scores indicate more anxiety). |
| Secondary | Penn State Worry Questionnaire-Past Day (PSWQ-PD) | Baseline (introductory session) and end of Training Day 3 (about 5 days) | Change in total score (range 0 to 60; higher scores indicate more worry). |
| Secondary | Beck Depression Inventory-II (BDI-II) | Baseline (introductory session) and end of Training Day 3 (about 5 days) | Change in total score (20-item version without the suicidal-thoughts item; range 0 to 60; higher scores indicate more depressive symptoms). |
| Secondary | Event vividness ratings | Training Day 1 and Training Day 3 | Change in vividness ratings (1 to 5) of trained versus untrained events, from Training Day 1 to Training Day 3. |
| Secondary | Event affect ratings | Training Day 1 and Training Day 3 | Change in distress (negative events) or joy (positive events) ratings (1 to 5), from Training Day 1 to Training Day 3. |
| Secondary | Cued recall | Training Day 3 | Percentage of Response Words recalled for trained versus untrained events on Training Day 3. |
| Other | PTSD Checklist for DSM-5 (PCL-5) total score | Training Day 3 | 20 items rated 0 (Not at all) to 4 (Extremely) for how much each problem bothered the participant, in relation to their worst event, during the past week (adapted from the standard past-month time frame). Total score range 0 to 80; higher scores indicate more severe PTSD symptoms (a worse outcome). |
| Other | Cambridge Selective Forgetting Inventory (CSFI) | Baseline (introductory session) | 32 items rated 0 to 3; total score range 0 to 96. Higher scores indicate a greater self-reported tendency to forget or disengage from unpleasant memories. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07891559/registered